Aminotransferase levels during treatment of rheumatoid arthritis with leflunomide in clinical practice

Annals of the Rheumatic Diseases

Volumn 62, Issue 4, 2003, Pages 379-

  Hoi, A ^a   Littlejohn, G O ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; LEFLUNOMIDE; METHOTREXATE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DISEASE SEVERITY; FOLLOW UP; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MONOTHERAPY; PATIENT COMPLIANCE; PATIENT MONITORING; POLYPHARMACY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0037377906     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.4.379     Document Type: Article

References (11)

1. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in act ve rheumatoid arthritis: a double-blind randomised multicentre trial. Lancet 1999;353:259-66.
2. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
3. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Arthritis Rheum 2000;43:495-505.
4. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65.
5. Scott DL, Smolen JS, Kalden JR, Van de Putte LBA, Larsen A, Kvien TK, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-23.
6. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomised, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared to methotrexate. Arthritis Rheum 2001;44:1984-92.
7. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
8. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Weisman M, et al. Combination of leflunomide and methotrexate in patients with active rheumatoid arthritis failing MTX monotherapy: an open-label extension study [abstract]. Arthritis Rheum 44(suppl 9):S549.
9. Kremer JM, Furst DE, Weinblatt ME, Blotner SD. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996;23:459-61.
10. Kremer JM, Alarcon GS, Lightfoot RW, Willkens RF, Furst DE, Willaims J, et al. Methotrexate for rheumatoid arthritis - suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.
11. Kremer JM. Not yet time to change the guidelines for monitoring methotrexate liver toxicity: they have served us well. J Rheumatol 2002;29:1590-2.